Management Plan for Acute Chest Pain Suggestive of ACS
Obtain a 12-lead ECG within 10 minutes of arrival and measure high-sensitivity cardiac troponin immediately, with repeat troponin at 1-2 hours if using hs-cTn assays or at 3-6 hours if using conventional assays. 1, 2
Immediate Assessment (0-10 Minutes)
ECG Acquisition and Interpretation
- Perform 12-lead ECG within 10 minutes of patient arrival and have it interpreted by an experienced physician immediately 3, 2, 1
- If initial ECG is non-diagnostic but symptoms persist with high clinical suspicion, repeat ECGs at 15-30 minute intervals during the first hour 3, 4
- Consider additional leads V7-V9 if posterior MI is suspected when standard leads are inconclusive 2, 5
Cardiac Biomarker Strategy
Use high-sensitivity troponin with the 0h/1h algorithm as the preferred approach 2:
- Draw initial hs-cTn at presentation (time 0)
- Repeat at 1 hour for hs-cTn assays 1, 2
- If conventional troponin is used instead, repeat at 3-6 hours 3, 1
- If first two measurements are inconclusive but clinical suspicion remains high, obtain additional testing at 3 hours 2
Observation Period (First 6-12 Hours)
Continuous Monitoring Requirements
Admit all patients with confirmed or suspected NSTEMI to a monitored unit with continuous rhythm monitoring until diagnosis is established or ruled out 2:
- For low-risk patients: rhythm monitoring up to 24 hours or until PCI (whichever comes first) 2
- For high-risk patients: rhythm monitoring for >24 hours 2
- Perform multi-lead ECG ischemia monitoring throughout observation period 6
Serial Assessment During Observation
- Obtain 12-lead ECG with each recurrence of chest pain and compare with tracings obtained when symptoms resolved 6
- Monitor for signs of hemodynamic instability (hypotension, pulmonary rales) 6
- Second troponin measurement at 6-12 hours if using older protocols 6
Risk Stratification
High-Risk Features Requiring Urgent Angiography 6
Identify patients with any of the following who need coronary angiography as soon as possible:
- Recurrent ischemia (chest pain or dynamic ST-segment changes, particularly ST-depression or transient ST-elevation)
- Elevated troponin levels
- Hemodynamic instability during observation
- Major arrhythmias (repetitive ventricular tachycardia, ventricular fibrillation)
- Diabetes mellitus
- Early post-infarction unstable angina
Low-Risk Patients
For patients with negative cardiac biomarkers, normal serial ECGs, and no recurrence of symptoms 7:
- Consider stress testing (preferably with imaging) or coronary CT angiography before discharge or within 72 hours 7
- May discharge from chest pain unit if evaluation remains negative
Initial Medical Treatment
Start immediately for all patients with suspected NSTE-ACS 6:
- Aspirin 75-150 mg daily (or clopidogrel if aspirin contraindicated)
- Clopidogrel (omit if CABG likely within 5 days)
- LMWH or unfractionated heparin
- Beta-blocker (or calcium antagonist if beta-blocker contraindicated)
- Nitrates (oral or IV) for persistent or recurrent chest pain
- Supplemental oxygen only if oxygen saturation <90% or respiratory distress 7
Common Pitfalls to Avoid
- Do not wait for troponin results to initiate reperfusion therapy in STEMI 8
- Do not discharge patients with a single negative troponin if drawn within 6 hours of symptom onset—serial measurements are mandatory 3, 5
- Do not use total CK, AST, or LDH as primary markers—cardiac troponin is the preferred biomarker 4
- Do not routinely administer supplemental oxygen to normoxic patients—it may increase coronary vascular resistance 7
Monitoring Frequency Summary
| Time Point | Action |
|---|---|
| 0 min (arrival) | 12-lead ECG, initial hs-cTn |
| 10 min | ECG interpretation complete |
| 15-30 min intervals | Repeat ECG if non-diagnostic and high suspicion |
| 1-2 hours | Repeat hs-cTn (or 3-6 hours for conventional) |
| 3 hours | Additional testing if inconclusive |
| 6-12 hours | Observation period with continuous monitoring |
| With each chest pain episode | 12-lead ECG |
| 24 hours minimum | Rhythm monitoring (longer if high-risk) |
The 2025 ACC/AHA guidelines and 2020 ESC guidelines provide the most current evidence-based framework, with the hs-cTn 0h/1h algorithm representing the most efficient diagnostic pathway when available 1, 2.